JP2015533511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533511A5 JP2015533511A5 JP2015541130A JP2015541130A JP2015533511A5 JP 2015533511 A5 JP2015533511 A5 JP 2015533511A5 JP 2015541130 A JP2015541130 A JP 2015541130A JP 2015541130 A JP2015541130 A JP 2015541130A JP 2015533511 A5 JP2015533511 A5 JP 2015533511A5
- Authority
- JP
- Japan
- Prior art keywords
- gram
- negative bacterium
- pneumoniae
- gene
- coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| US61/723,408 | 2012-11-07 | ||
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186302A Division JP6833785B2 (ja) | 2012-11-07 | 2018-10-01 | 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533511A JP2015533511A (ja) | 2015-11-26 |
| JP2015533511A5 true JP2015533511A5 (enExample) | 2016-12-22 |
| JP6412875B2 JP6412875B2 (ja) | 2018-10-24 |
Family
ID=49552366
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541130A Expired - Fee Related JP6412875B2 (ja) | 2012-11-07 | 2013-11-07 | 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造 |
| JP2018186302A Expired - Fee Related JP6833785B2 (ja) | 2012-11-07 | 2018-10-01 | 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018186302A Expired - Fee Related JP6833785B2 (ja) | 2012-11-07 | 2018-10-01 | 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (enExample) |
| EP (3) | EP3444352B1 (enExample) |
| JP (2) | JP6412875B2 (enExample) |
| KR (1) | KR20150079964A (enExample) |
| CN (1) | CN105008539B (enExample) |
| AU (2) | AU2013343520B2 (enExample) |
| BR (1) | BR112015010283A8 (enExample) |
| CA (2) | CA2889767C (enExample) |
| EA (1) | EA201590705A1 (enExample) |
| ES (3) | ES2713166T3 (enExample) |
| IL (1) | IL238586A0 (enExample) |
| MX (1) | MX366912B (enExample) |
| SG (1) | SG11201503308XA (enExample) |
| TR (1) | TR201903066T4 (enExample) |
| WO (1) | WO2014072405A1 (enExample) |
| ZA (1) | ZA201503097B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010322454B2 (en) * | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| US11220676B2 (en) * | 2013-10-11 | 2022-01-11 | Glaxosmithkline Biological Sa | Methods of host cell modification |
| EA035991B9 (ru) | 2014-02-24 | 2020-10-21 | Глаксосмитклайн Байолоджикалс С.А. | Новый полисахарид и его применения |
| SI3131577T1 (sl) * | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
| SG11201700325SA (en) * | 2014-08-08 | 2017-02-27 | Glycovaxyn Ag | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| AU2016224006B8 (en) * | 2015-02-26 | 2020-03-19 | Vaxnewmo Llc | Acinetobacter O-oligosaccharyltransferases and uses thereof |
| GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) * | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| WO2019090138A2 (en) * | 2017-11-04 | 2019-05-09 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Immunogenic conjugates and methods of use thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| WO2019241672A2 (en) | 2018-06-16 | 2019-12-19 | Vaxnewmo Llc | Glycosylated comp pilin variants, methods of making and uses thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| US12350342B2 (en) | 2018-12-21 | 2025-07-08 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN112369722B (zh) * | 2020-05-08 | 2023-03-17 | 湖北中烟工业有限责任公司 | 加热不燃烧装置和温度控制方法 |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| CA3185719A1 (en) * | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
| US20230293657A1 (en) | 2020-06-25 | 2023-09-21 | Glaxosmithkline Biologicals Sa | Vaccine |
| KR20230043157A (ko) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 다가 백신 조성물 및 이의 용도 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| EP4452308A1 (en) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2638595A (en) * | 1994-05-16 | 1995-12-05 | Uab Research Foundation, The | (streptococcus pneumoniae) capsular polysaccharide genes and flanking regions |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| CA2477794C (en) | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| JP5356807B2 (ja) | 2005-05-11 | 2013-12-04 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| CA2756170C (en) * | 2009-03-23 | 2019-04-02 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
| KR20120085240A (ko) | 2009-07-17 | 2012-07-31 | 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. | 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합 |
| ES2844596T3 (es) | 2010-05-06 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Vacunas de bioconjugados de bacterias grampositivas capsulares |
| TR201904022T4 (tr) * | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
-
2013
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh not_active Expired - Fee Related
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en not_active Ceased
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Withdrawn
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en not_active Ceased
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja not_active Expired - Fee Related
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en not_active Ceased
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en not_active Expired - Fee Related
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533511A5 (enExample) | ||
| AU2017279688B2 (en) | Production of recombinant vaccine in e. coli by enzymatic conjugation | |
| HRP20240847T1 (hr) | Novi polisaharid i njegove upotrebe | |
| Wen et al. | Bacterial capsules | |
| JP2017036303A5 (enExample) | ||
| BR112014018815B1 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
| JP6682451B2 (ja) | 改変型宿主細胞およびその使用 | |
| CN104487086B (zh) | 无动物源的不含酒精的疫苗组合物及其制备方法 | |
| US11596677B2 (en) | Induction of protective immunity against antigens | |
| JP7699543B2 (ja) | Ｏ結合型グリコシル化認識モチーフ | |
| US10716839B2 (en) | Compositions and methods for producing bacterial conjugate vaccines | |
| CA3050724A1 (en) | Induction of protective immunity against antigens | |
| WO2006065137A2 (en) | Novel efficient production process for capsular polysaccharides of pathogenic grampositive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram- positive bacteria | |
| Baliban et al. | Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS: FliC glycoconjugates in infant and adult mice | |
| CN106110316A (zh) | 一种肺炎球菌结合物组合疫苗的制备方法 | |
| Schuster et al. | Immunogenicity and protective efficacy against Salmonella C2-C3 infection in mice immunized with a glycoconjugate of S. Newport Core-O polysaccharide linked to the homologous serovar FliC protein | |
| ES2933027T3 (es) | Purificación de polisacáridos secretados de S. agalactiae | |
| CN108774628A (zh) | 合成致新生儿脑膜炎大肠杆菌糖蛋白结合疫苗的大肠杆菌工程菌及用途 | |
| Chan et al. | The new first-line defense: the potential of nasopharyngeal colonization in vaccine strategies | |
| CN115362177A (zh) | 糖类的纯化 | |
| Seo et al. | Characterization of antigenic determinants in ApxIIA exotoxin capable of inducing protective immunity to Actinobacillus pleuropneumoniae challenge | |
| JP2011511630A (ja) | Ｐ．ｍｕｌｔｏｃｉｄａのｆｕｒ細胞およびその外膜タンパク質の抽出物によるＰａｓｔｅｕｒｅｌｌａｍｕｌｔｏｃｉｄａに対する異種性の防御 | |
| MacLennan et al. | New Approaches for Needed Vaccines: Bacteria | |
| BR122024027321A2 (pt) | Composições imunogênicas de vacina | |
| HK40076438A (en) | Purification of saccharides |